Navigation Links
Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
Date:1/16/2008

PHOENIX, Jan. 16 /PRNewswire-FirstCall/ -- Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company, announced today that the season-to-date incidence of illness for the 2007/2008 cold season (which generally runs October through March) has been the lowest since Zicam was introduced in 1999 according to the industry standard tracking service (SDI FAN). The lower level incidence of colds in the general population has affected the amount of reorders the Company received in the quarter ended December 31, 2007. The Company anticipates reporting sales for the quarter ended December 31, 2007 below the comparative quarter in the prior year, and net loss and loss per share will be on par with the prior year's quarter.

Although the most recent tracking data is showing an uptick in the incidence of illness, the Company is updating its previously issued guidance for fiscal 2008 (ending March 31, 2008). If the cold season continues in accordance with the current trend, the Company anticipates fiscal 2008 net sales will be equal to or up to 5% above the $97.6 million recorded in the twelve months ended March 31, 2007. Based on the updated level of sales, the Company expects to report net income between $9.0 million and $10.0 million, or $0.90 to $1.00 per share. The Company's previously issued fiscal 2008 guidance anticipated net sales would increase 5-15% over the $97.6 million recorded for the trailing twelve months ended March 31, 2007 and net income would be in the range of $9.3 million to $10.8 million

Carl Johnson, President and Chief Executive Officer, said, "Although the slow start to the cold season requires us to reduce our annual guidance, Zicam grew to be the 5th largest cough and cold brand at retail
'/>"/>

SOURCE Matrixx Initiatives, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference
3. FDA Updates Prescription Guidelines for Blood Thinner
4. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
5. Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
6. MedQuist Updates Status of Outstanding SEC Filings
7. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
8. ADA Updates Environmental Recommendations for Handling Waste
9. West Pharmaceutical Services Updates Annual Guidance
10. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
11. WallSt.net Updates Investment Community Through All-New Interview With Ingen Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... Abilene, Texas (PRWEB) December 26, 2014 Yisrayl ... has written an open letter in light of the Ferguson, ... year history of civil unrest and explains why it has ... the reason mankind was even created. He says there is ... in detail. Yisrayl also says there is a set of ...
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Sterilizers manufacturers and is a valuable source of ... the industry. This report provides a basic overview of ... In this part, the report presents the company profile, ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... 25 The HHS Office of HIV/AIDS Policy,s AIDS.gov will ... with a special focus on reducing HIV/AIDS-related stigma and promoting ... World AIDS Day will also mark the second anniversary of ... and resources. , , AIDS.gov ...
... guide treatment choices, researchers say , , TUESDAY, Nov. 25 ... genetic model for predicting the risk of recurrence in ... a team at the Duke Institute for Genome Science ... to chemotherapy and targeted therapy regimens. , The researchers ...
... available in Spanish . , A new ... the first time since the report was first issued in ... are decreasing for both men and women, driven largely by ... The report notes that, although the decreases in overall ...
... , , HARRISBURG, Pa., Nov. ... West Middlesex Area School District, the Pennsylvania Department of Health ... Middlesex Junior/Senior High School on Nov. 19 and Nov. 24. ... tetanus/diphtheria/pertussis vaccine was given to approximately 560 parents, students, and ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that the ... Conference on Tuesday, December 2, 2008 at,noon Eastern Time. The ... through a link on the investors section of Gen-Probe,s website ... days following,the event. , ...
... with chronic obstructive pulmonary disorder must weigh risks, benefits, ... A new review of existing data confirms that some ... with the lung disease known as chronic obstructive pulmonary ... raise the risk of pneumonia in patients with COPD, ...
Cached Medicine News:Health News:HHS' AIDS.gov to Use Blogs, Virtual Worlds, and Social Networks to Deliver HIV Information for World AIDS Day 2008 2Health News:Gene Test Could Predict Colon Cancer's Return 2Health News:Annual report to the nation finds declines in cancer incidence and death rates 2Health News:Annual report to the nation finds declines in cancer incidence and death rates 3Health News:Annual report to the nation finds declines in cancer incidence and death rates 4Health News:Annual report to the nation finds declines in cancer incidence and death rates 5Health News:Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 3
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
(Date:12/24/2014)... , December 24, 2014 ... at an average rate of 8.1%. The US has ... knee and spine surgeries are the common orthopedic procedures ... have a lower penetration. Increased number of product recalls ... Non-metallic orthopedic devices have gained popularity in the industry ...
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Reserve" May Also Affect,Alzheimer's Risk -, WASHINGTON, June ... treating risk factors for heart disease and stroke,such ... the progression,of Alzheimer's disease, according to research reported ... Prevention,of Dementia in Washington, DC. , Two new ...
... Jun 09, 2007 (MARKET WIRE via COMTEX ... owned subsidiary of Endo,Pharmaceuticals Holdings Inc. (NASDAQ: ... randomized, double-blind, placebo-controlled,clinical trial evaluating Frova (frovatriptan ... treatment in women with,difficult-to-treat menstrual migraine (MM). ...
Cached Medicine Technology:Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 2Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 3Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 4Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 6Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 7Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7
... a scientifically advanced multinutrient that ... and full body health. It ... including a diverse array of ... lycopene and OptiBerry and important ...
... Ocuvite® Extra vitamin and mineral supplements ... original formula plus more. Ocuvite ... and higher levels of vitamins C ... also contains other antioxidants and minerals ...
HydroEye is an exclusive formulation designed to provide dry eye relief and support the body's natural tear formation. Like all ScienceBased Health formulations, it is produced in softgel form for ma...
Expert QC data management solution...
Medicine Products: